Nigeria’s Ministery of Health champions early cancer detection through strategic innovation

July 1, 2025

The Nigerian Ministry of Health is taking decisive steps to address the urgent need for early cancer detection across the country. “It is time for Nigeria to fully embrace the power of early detection. This is not a luxury—it is a necessity in our battle against cancer,” stated Dr. Iziaq Kunle Salako, Minister of Health and Social Welfare.

Dr. Salako’s remarks come at a critical time, as cancer continues to pose a major public health challenge in Nigeria. In 2022, the country recorded over 127,000 new cancer cases and more than 79,000 cancer-related deaths, with numbers projected to rise. Despite the growing burden, access to advanced detection and treatment options remains limited for many Nigerians. To address this, the Ministry of Health convened a high-level forum on June 25th and 26th, bringing together medical experts, policymakers, stakeholders, and strategic partners to explore innovative strategies for strengthening Nigeria’s cancer care infrastructure.

“Strategic partnerships are key in this battle against cancer,” Dr. Salako emphasised. One such partnership is between Excellion International Limited (Nigeria) and OncoInv (The Netherlands), aimed at making multi-cancer early detection widely available in Nigeria through the implementation of OncoSeek®.

Their flagship innovation, OncoSeek®, is a patient-friendly blood test that detects nine types of cancer simultaneously—without the need for biopsies or imaging equipment. The blood sample is analysed in a laboratory, and the results are processed using machine learning to generate a detection score. OncoSeek® is fully GDPR-compliant and operates securely in the cloud.

About OncoInv

OncoInv offers OncoSeek® on a not-for-profit basis in Low- and Middle-Income Countries to ensure affordability and accessibility. It is a wholly owned subsidiary of the non-profit foundation Inspire2Live. Learn more at www.oncoinv.org.

About Excellion International Limited

Located in OPIC Estate, Isheri-North Lagos, Excellion is a pharmaceutical firm dedicated to promotive healthcare solutions for vulnerable populations. Through its partnership with OncoInv, Excellion is actively promoting OncoSeek® in Nigeria. The company’s mission is to become a leading provider of high-impact healthcare products and technologies by leveraging innovation, research, ICT, and science to improve access to care. Learn more at www.xcellioninternation.com

About Inspire2Live

Inspire2Live is an international patient advocacy organization committed to inspiring and empowering patients, researchers, and clinicians to collaborate in the prevention, treatment, and elimination of cancer. Operating globally with respect for local contexts, Inspire2Live drives initiatives that make healthcare more patient-centric. Visit www.inspire2live.org for more information.

More news

Accelerating early cancer detection in Latin America: Biotecgen enters strategic partnership with OncoInv

June 10th, 2025

Biotecgen (Colombia) and OncoInv (The Netherlands) have joined forces to make multi-cancer early detection accessible in Colombia. Biotecgen will offer OncoSeek®, a patient-friendly solution for cancer detection, requiring only a blood sample to detect 9 types of cancer...

Read more
Longevity Medical Institute launches advanced cancer early detection program in Mexico using oncoseek test

April 7th, 2025

Longevity Medical Institute™ (LMI), a leading centre for regenerative medicine and diagnostics in Mexico, has partnered with OncoInv to incorporate the OncoSeek® test into one of the most advanced and accessible cancer detection programs in Latin America...

Read more
BIOS and OncoInv have joined in partnership to bring cancer detection to Pakistan

March 3rd, 2025

BIOS (Pakistan) and OncoInv (The Netherlands) have joined forces to make multi-cancer early detection accessible in Pakistan. OncoSeek® is a patient-friendly solution for cancer detection, requiring only a blood sample...

Read more